Maxcyte (MXCT) Accumulated Depreciation (2020 - 2026)

Maxcyte (MXCT) has 7 years of Accumulated Depreciation data on file, last reported at $18.3 million in Q1 2026.

• On a quarterly basis, Accumulated Depreciation rose 16.97% year-over-year to $18.3 million in Q1 2026; TTM through Mar 2026 was $18.3 million, a 16.97% increase from a year earlier, with the FY2025 full-year figure at $17.3 million, up 27.02% from the prior year.
• Accumulated Depreciation for Q1 2026 stood at $18.3 million, up from $17.3 million in the prior quarter.
• Over the last five years, Accumulated Depreciation for MXCT reached as high as $18.3 million in Q1 2026 and fell as low as $4.8 million in Q1 2022.
• Historically, Accumulated Depreciation has averaged $11.2 million across 5 years, with a median of $11.4 million in 2024.
• Across the five-year window, Accumulated Depreciation jumped 65.6% in 2023 and climbed 16.97% in 2026, its largest moves.
• Year by year, Accumulated Depreciation stood at $6.3 million in 2022, then soared by 63.92% to $10.3 million in 2023, then surged by 32.14% to $13.6 million in 2024, then rose by 27.02% to $17.3 million in 2025, then grew by 5.83% to $18.3 million in 2026.
• Per Business Quant data, the three most recent Accumulated Depreciation figures were $18.3 million in Q1 2026, $17.3 million in Q4 2025, and $17.0 million in Q3 2025.